~
Ovarian cancer is the fifth leading cause of cancer death among American women. In 2014, it killed more than 14,000 women. Given the rate of diagnosis, there are more women in the pipeline for next year and the next and the one after that. If you are not fighting this disease, you probably know someone who is.
 
That’s yesterday’s news. Today’s news is that the Federal Drug Administration is willing to support continued research into a treatment option that is based on Dronabinol, a cannabinoid, which is one of the many non-THC derivatives of the cannabis plant. The prospects for the future include not only better treatment options for those diagnosed with ovarian cancer, but more research into the largely untouched medical potential of cannabis.
 
Ovarian Cancer
 
It is a hard disease to detect and treat. The symptoms of the early stages, when it is most curable, are subtle and many women dismiss them. It is resistant to current treatments, particularly after the first drug round. Much depends on the stage at which this kind of cancer is diagnosed, but the overall five-year survival rate is less than half.
 
So, message number one for all you ladies out there, especially if you are white and over 60, is to get yourselves into the doctor’s office for a checkup.
 
Treatment Options and Issues
 
When the diagnosis is ovarian cancer, doctors often recommend aggressive measures, including two or more different types of treatments. The options include surgery, chemotherapy, hormone therapy, targeted therapy and radiation therapy. Each can have life-threatening complications.
 
Insys Therapeutic Inc.’s Liposomal Encapsulated Paclitaxel, a drug which contains Dronabinol, may soon be part of the package of options. In drug trials it has reportedly been effective in the treatment of the nausea and vomiting associated with cancer chemotherapy as well as anorexia associated with weight loss in patients with AIDS.
 
What’s New?
 
Cannabis as medicine is not new; the recognition that it may be helpful in treating nausea is not new, but the investment incentives that come with FDA greenlighting are new. LEP’s special status under The Orphan Drug Act, qualifies Insys for various development incentives, including tax credits for qualified clinical testing and a seven-year period of U.S. marketing exclusivity upon approval. These incentives may support LEP’s development.
 
Broader Implications
 
Additional treatment options for patients undergoing chemotherapy or who are otherwise fighting weight loss are important. Development incentives for drug companies should expand those options. That is good for drug companies.
 
The larger investment picture, however, involves the recognition that cannabis and cannabis derivatives may have acceptable medical uses that are inconsistent with its classification as a Schedule I drug. Every recognized medical use helps to build a stronger case for descheduling. Were cannabis removed from the Controlled Substance Act’s schedules, research into other medical uses would be easier to fund. Investors would be more willing to support research. The virtuous circle of growth and investment could begin to function.
 
Anne Wallace ~ MJI News ~ January 29, 2015
 
~
September 17, 2019

Mouth On Fire? Here’s How Cannabis Can…

Researchers accidentally proved that marijuana has the potential to ease the pain of capsaicin, which is the chemical responsible for…
September 17, 2019

USDA hemp regulations draft sent to White…

The U.S. Department of Agriculture has completed a long-awaited draft of federal regulations for the cultivation of hemp and submitted…
September 17, 2019

Blingy vaporizers and gold rolling papers: luxury…

As marijuana becomes more acceptable and its consumer base grows, companies are aiming for prestige.
September 17, 2019

Marijuana Banking Bill Gains Momentum With One…

The most cannabis-friendly Congress in history is back from its August recess, and lawmakers are already making key moves to…
September 16, 2019

How Florida's 55 and older communities are…

"They can get off many of their expensive meds and that is very appealing to seniors."
September 16, 2019

This Is the First Hemp Strain to…

As the high-CBD strain that won over skeptics and helped change the national conversation around medical marijuana, Charlotte’s Web may…
September 13, 2019

Cannabis on Cape Cod: A Fledgling Industry…

For the moment, the Triple M medical cannabis facility in Mashpee, Massachusetts is the only cannabis dispensary on Cape Cod.
September 13, 2019

In era of legal pot, can police…

Sniff and search is no longer the default for police in some of the 33 states that have legalized marijuana.
September 13, 2019

GOP Senate Chair Says He Plans Marijuana…

The Republican chair of the Senate Banking Committee said on Thursday that his panel will hold a vote on legislation…
September 12, 2019

What if NY legalizes marijuana but NJ…

While the debate over New Jersey marijuana legalization has largely become a question of "will they or won't they," law…